Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249818 | 0.93 | GAA (0.41) | GRIN2BCHRM2CHRM3OPRM1OPRD1 | |
| SCHEMBL4244127 | 0.88 | KMT2A (0.45) | GRIN2BCHRM2CHRM3ACHE | |
| SCHEMBL4249836 | 0.84 | GRIN2B (0.40) | GRIN2BCHRM2CHRM3S1PR1S1PR5 | |
| SCHEMBL4238209 | 0.80 | PKM (0.42) | CHRM2CHRM3S1PR1S1PR5ACHE | |
| SCHEMBL4248188 | 0.79 | ACHE (0.42) | CHRM2CHRM3NPSR1S1PR1S1PR5 | |
| SCHEMBL4248181 | 0.79 | ACHE (0.38) | GRIN2BS1PR1S1PR5ACHE | |
| SCHEMBL4237568 | 0.79 | KDM4E (0.42) | GRIN2BCHRM2CHRM3OPRM1 | |
| SCHEMBL4240892 | 0.79 | SIGMAR1 (0.42) | GRIN2BACHE | |
| SCHEMBL4241455 | 0.77 | SIGMAR1 (0.41) | GRIN2BS1PR1S1PR5ACHE | |
| SCHEMBL4238450 | 0.77 | MEN1 (0.41) | GRIN2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | GRIN2B 421/4885CHRM2 2/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.